Exacerbation of financial burden of insulin and overall glucose‐lowing medications among uninsured population with diabetes
Exacerbation of financial burden of insulin and overall glucose‐lowing medications among uninsured population with diabetes is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Exacerbation of financial burden of insulin and overall glucose‐lowing medications among uninsured population with diabetes have?
Exacerbation of financial burden of insulin and overall glucose‐lowing medications among uninsured population with diabetes has 17 citations in the OpenAlex counts ScholarIQ stores.
When was Exacerbation of financial burden of insulin and overall glucose‐lowing medications among uninsured population with diabetes published?
Exacerbation of financial burden of insulin and overall glucose‐lowing medications among uninsured population with diabetes has 2023 year in the ScholarIQ index.
What is the open-access status of Exacerbation of financial burden of insulin and overall glucose‐lowing medications among uninsured population with diabetes?
Exacerbation of financial burden of insulin and overall glucose‐lowing medications among uninsured population with diabetes has gold oa status in the ScholarIQ index.
What is the DOI of Exacerbation of financial burden of insulin and overall glucose‐lowing medications among uninsured population with diabetes?
The DOI for Exacerbation of financial burden of insulin and overall glucose‐lowing medications among uninsured population with diabetes is on the source record.
What is the PMID of Exacerbation of financial burden of insulin and overall glucose‐lowing medications among uninsured population with diabetes?
The PMID for Exacerbation of financial burden of insulin and overall glucose‐lowing medications among uninsured population with diabetes is on the source record.
What is the OpenAlex record for Exacerbation of financial burden of insulin and overall glucose‐lowing medications among uninsured population with diabetes?
The OpenAlex for Exacerbation of financial burden of insulin and overall glucose‐lowing medications among uninsured population with diabetes is on the source record.